TAC1 and adenomyosis: Interestingly, the authors were able to reduce the incidence of adenomyosis by preadministration of the neurokinin receptor antagonist, aprepitant, where the receptor mediates downstream targets of Substance P and local inflammation hypothesized to play a role in adenomyosis and endometriosis pathophysiology (Hao et al., 2020).